BioGaia AB: Interim Management Statement January – March 2024
FIRST QUARTER 2024(For balance sheet items, figures in parentheses refer to year-end 2023 figures. For income statement and cash flow items, they refer to the same period last year). Net sales amounted to SEK 369.8 million (365.8), an increase of SEK 4.0 million, or 1% (excluding foreign exchange effects, 2%). Net sales in the Pediatrics segment amounted to SEK 292.3 million (306.0), a decrease of 4% (excluding foreign exchange effects a decrease of 4%). Net sales in the Adult Health segment amounted to SEK 74.8 million (56.6), an increase of 32% (excluding foreign exchange